Quick Answer
vTv Therapeutics Inc. reported Operating Income Loss of -$32.81 million for the year ending 2025.
- vTv Therapeutics Inc. showed a decrease of -35.7% in Operating Income Loss from 2024 to 2025.
- This data is from vTv Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), vTv Therapeutics Inc.'s Operating Income Loss has grown by 8.4%.
- Historical annual values: Fiscal year 2025: -$32.81 million | Fiscal year 2024: -$24.18 million | Fiscal year 2023: -$25.50 million | Fiscal year 2022: -$22.54 million | Fiscal year 2021: -$21.66 million | Fiscal year 2020: -$11.85 million | Fiscal year 2019: -$20.89 million | Fiscal year 2018: -$19.82 million | Fiscal year 2017: -$50.68 million | Fiscal year 2016: -$55.02 million | Fiscal year 2015: -$38.14 million | Fiscal year 2014: -$28.90 million | Fiscal year 2013: -$35.83 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: